ASX, BIOTECHS UP: PSIVIDA UP 14%
February 9th 2007 07:01
Biotech Daily Market Report Friday February 9, 2007
THE MARKET
Seventeen of the Biotech Daily Top 40 stocks were up, 14 stocks fell and nine traded unchanged. Eleven of the Top 20 rose and eight fell, while six of the Second 20 rose and six fell. All falls were less than four percent.
Psivida was best, up three cents or 13.95 percent to 24.5 cents with 4.1 million shares traded. Acrux climbed eight cents or 8.42 percent to $1.03 with just under one million shares changing hands, Neuren was up 4.5 cents or 8.26 percent to 59 cents and Alchemia was up 8.5 cents or 7.69 percent to $1.19 with 597,212 shares traded.
Biosignal, Mesoblast, Peplin and Pharmaxis were all down more than three percent; Novogen, Polartechnics, Portland and Resmed fell more than two percent; with CSL, Evogenix, Metabolic, Optiscan, Phosphagenics and Prana down more than one percent.
TODAY’S NEWS
* CHEMGENEX TO RAISE UP TO $21m FOR CEFLATONIN TRIALS
* SOLAGRAN ST PETERSBURG PRESENTATION TIMELY
* CHEMEQ RECEIVERS ON HOLD PENDING APPEAL
* BIOTA BOUYANT ON RELENZA ROYALTIES
* CYTOPIA H1 LOSS DOWN ON NOVARTIS LICENCE, ALCHEMIA SALE
* ARIXTRA SALES UP 143% GOOD FOR ALCHEMIA
* MESOBLAST’S PROF SILVIU ITESCU SELLS 6m SHARES
* PHARMAUST EXTENDS TRADING HALT TO SUSPENSION
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
ASX, BIOTECHS UP: PSIVIDA UP 14%
THE MARKET
Seventeen of the Biotech Daily Top 40 stocks were up, 14 stocks fell and nine traded unchanged. Eleven of the Top 20 rose and eight fell, while six of the Second 20 rose and six fell. All falls were less than four percent.
Psivida was best, up three cents or 13.95 percent to 24.5 cents with 4.1 million shares traded. Acrux climbed eight cents or 8.42 percent to $1.03 with just under one million shares changing hands, Neuren was up 4.5 cents or 8.26 percent to 59 cents and Alchemia was up 8.5 cents or 7.69 percent to $1.19 with 597,212 shares traded.
Biosignal, Mesoblast, Peplin and Pharmaxis were all down more than three percent; Novogen, Polartechnics, Portland and Resmed fell more than two percent; with CSL, Evogenix, Metabolic, Optiscan, Phosphagenics and Prana down more than one percent.
TODAY’S NEWS
* CHEMGENEX TO RAISE UP TO $21m FOR CEFLATONIN TRIALS
* SOLAGRAN ST PETERSBURG PRESENTATION TIMELY
* CHEMEQ RECEIVERS ON HOLD PENDING APPEAL
* BIOTA BOUYANT ON RELENZA ROYALTIES
* CYTOPIA H1 LOSS DOWN ON NOVARTIS LICENCE, ALCHEMIA SALE
* ARIXTRA SALES UP 143% GOOD FOR ALCHEMIA
* MESOBLAST’S PROF SILVIU ITESCU SELLS 6m SHARES
* PHARMAUST EXTENDS TRADING HALT TO SUSPENSION
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 55 |
| Vote |
Add To: 
subscribe to this blog